Xenon Pharmaceuticals (XENE) Q3 2025 earnings summary

Executive summary

• Completed randomization of 380 patients in phase III X-TOLE2 study for azetukalner in focal onset seizures, exceeding the original target; topline data expected early 2026 and NDA preparation underway.

• Expanding azetukalner's development into neuropsychiatric indications, including major depressive disorder (MDD) and bipolar depression (BPD), with multiple phase III trials ongoing.

• Early-stage pipeline advancing with Nav1.7 and Kv7 modulators in phase I studies for pain, and Nav1.1/partnered programs progressing in preclinical or phase I studies for epilepsy.

• Appointed new CFO to support anticipated commercialization and financial strategy.

• $7.5 million milestone revenue recognized from Neurocrine Biosciences collaboration in 2025.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $555.3 million as of September 30, 2025, down from $754.4 million at year-end 2024.

• Net loss widened to $90.9 million for Q3 2025, compared to $62.8 million in Q3 2024; net loss for the nine months ended September 30, 2025, was $240.6 million.

• Research and development expenses rose to $77.1 million in Q3 2025, up from $57.0 million in Q3 2024.

• General and administrative expenses increased to $19.3 million in Q3 2025, reflecting higher headcount and pre-commercialization activities.

• Collaboration revenue of $7.5 million recognized in the nine months ended September 30, 2025.

Outlook and guidance

• Sufficient cash runway projected to fund operations into 2027, supporting late-stage and early-stage clinical programs.

• Topline data from X-TOLE2 expected in early 2026, with NDA submission planned if results are positive.

• Ongoing phase III studies in MDD (X-NOVA2, X-NOVA3) and BPD (X-ACKT/X-CEED), with guidance on data timing to be provided as studies progress.

• Phase I studies for pain programs expected to complete in early 2026, with potential phase II proof-of-concept studies to follow.

• Additional capital will be required to support future development and commercialization efforts.